Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer

Activation of CDK2 in triple negative breast cancer (TNBC) can contribute to non-canonical phosphorylation of a TGFβ signaling component, Smad3, promoting cell proliferation and migration. Inhibition of CDK2 was shown to decrease breast cancer oncogenesis. Eribulin chemotherapy was used effectively...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Shreyas S., Stoehr, Jenna, Dokic, Danijela, Wan, Lei, Decker, Joseph T., Konopka, Kristine, Thomas, Alexandra L., Wu, Jia, Kaklamani, Virginia G., Shea, Lonnie D., Jeruss, Jacqueline S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663565/
https://www.ncbi.nlm.nih.gov/pubmed/29137393
http://dx.doi.org/10.18632/oncotarget.20202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663565/
https://www.ncbi.nlm.nih.gov/pubmed/29137393
http://dx.doi.org/10.18632/oncotarget.20202

Ejemplares similares